Brokerages predict that MeiraGTx Holdings PLC (NASDAQ:MGTX) will report earnings per share (EPS) of ($0.67) for the current quarter, according to Zacks. Zero analysts have issued estimates for MeiraGTx’s earnings. The company is scheduled to announce its next quarterly earnings report on Thursday, February 14th.
According to Zacks, analysts expect that MeiraGTx will report full-year earnings of ($4.44) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($4.36) per share, with EPS estimates ranging from ($4.74) to ($3.97). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for MeiraGTx.
MeiraGTx (NASDAQ:MGTX) last posted its earnings results on Thursday, November 8th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.01).
MGTX has been the subject of a number of research reports. Chardan Capital initiated coverage on shares of MeiraGTx in a report on Thursday, August 23rd. They issued a “buy” rating for the company. Zacks Investment Research raised shares of MeiraGTx from a “sell” rating to a “hold” rating in a report on Friday, October 5th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. MeiraGTx has a consensus rating of “Buy” and an average price target of $23.67.
Institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. acquired a new position in shares of MeiraGTx in the second quarter valued at approximately $229,000. Dean Capital Investments Management LLC acquired a new position in shares of MeiraGTx in the second quarter valued at approximately $458,000. FMR LLC acquired a new position in shares of MeiraGTx in the second quarter valued at approximately $664,000. Millennium Management LLC acquired a new position in shares of MeiraGTx in the second quarter valued at approximately $923,000. Finally, BlackRock Inc. acquired a new position in shares of MeiraGTx in the third quarter valued at approximately $1,968,000. 22.77% of the stock is owned by institutional investors.
MGTX stock opened at $12.93 on Wednesday. MeiraGTx has a 12 month low of $7.98 and a 12 month high of $15.49.
MeiraGTx Company Profile
MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases.
Further Reading: Consumer behavior in bull markets
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.